| CytoSorbents Corporation | |
| Traded As: | NASDAQ: Russell 2000 Component |
| Type: | Public |
| Industry: | Critical care |
| Founders: | --> |
| Hq Location City: | Princeton, New Jersey |
| Hq Location Country: | US |
| Areas Served: | --> |
| Num Employees: | 160 |
| Products: | CytoSorb |
| Revenue: | US$ 41.0 Mio. (2020)[1] |
| Owners: | --> |
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.[2] [3] [4]
CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011[5]) — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.[6] [7]
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns (Toraymyxin), which failed to show significance in a clinical trial for sepsis.[8] The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy.[9] Clinicaltrials.gov is giving an overview over running research projects.[10]
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.[11] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.[12] [13]